SCHEDULE: Avoro Capital Discloses 0.6% Stake in Blueprint Medicines

Avoro Capital Advisors and Behzad Aghazadeh have reported a beneficial ownership of 0.6% of Blueprint Medicines Corp's common stock.

Summary

• Avoro Capital Advisors LLC and Behzad Aghazadeh have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Blueprint Medicines Corp.
• The reporting persons, Avoro Capital Advisors LLC (an investment adviser) and Dr. Behzad Aghazadeh (its portfolio manager and controlling person), collectively beneficially own 375,000 shares of Blueprint Medicines Corp's common stock.
• This ownership represents 0.6% of the total class of securities outstanding.
• The percentage is calculated based on 64,733,629 shares of Common Stock outstanding as of June 12, 2025, as reported in the Issuer's Schedule 14D-9.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, providing factual information without indicating positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment firm and its principal, indicating a passive investment stake in a publicly traded biotechnology or pharmaceutical company. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes by institutional investors, which can influence market perception of the stock's liquidity and investor base.

Key Dates

Keywords

Blueprint Medicines Corp, Avoro Capital Advisors, Behzad Aghazadeh, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Advisory